Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 530) to provide for a study by the National Academies of Sciences, Engineering, and Medicine on the prevalence and mortality of cancer among individuals who served as Active Duty aircrew in the Armed Forces, and for other purposes, as amended. The Clerk read the title of the bill. The text of the bill is as follows: H.R. 530 Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``ACES Act''. SEC. 2. NATIONAL ACADEMIES STUDY ON PREVALENCE AND MORTALITY OF CANCER AMONG INDIVIDUALS WHO SERVED AS ACTIVE DUTY AIRCREW IN THE ARMED FORCES. (a) Agreement.-- (1) In general.--Not later than 30 days after the date of the enactment of this Act, the Secretary of Veterans Affairs shall seek to enter into an agreement with the National Academies of Sciences, Engineering, and Medicine (in this section referred to as the ``National Academies''), under which the National Academies shall conduct a study on the prevalence and mortality of cancers among covered individuals. (2) Deadline.-- (A) Date.--The Secretary shall finalize the agreement under paragraph (1) by not later than 60 days after the date on which the Secretary enters negotiations with the National Academies with respect to such agreement.…
On the recordMay 5, 2025
Share & report
More from Jack Bergman
Nov 29, 2023
Mr. Speaker, it is so interesting to walk in and wonder if you have walked into the middle of something. Mr. Speaker, I appreciate the gentlewoman for yielding, and I am honored to join my colleagues today in highlighting the…
Dec 4, 2023
Mr. Speaker, while we are considering this bill today, I would remind my colleagues that this legislation is also a part of a comprehensive veterans package being negotiated between the House and Senate Veterans' Affairs Committees. Mr…
Nov 13, 2023
Will the publication of phase three clinical trial results with that last month all signs point toward MDMA assisted therapy receiving FDA approval within the next year.
Apr 12, 2024
Mr. Speaker, had I been present, I would have voted ``yea'' on rollcall No. 112.





